Ofatumumab
| Evidence Level: L2 | Predicted Indications: 8 |
Table of Contents
Ofatumumab: From Chronic Lymphocytic Leukemia to Follicular Lymphoma
One-Sentence Summary
Ofatumumab is a fully human anti-CD20 monoclonal antibody originally developed and approved for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The TxGNN model predicts it may also be effective for Follicular Lymphoma (FL), a related CD20⁺ indolent B-cell malignancy, with 15 clinical trials and 20 publications currently available as supporting evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) — established via global approval history documented in the literature evidence; no India-specific license record exists |
| Predicted New Indication | Follicular Lymphoma |
| TxGNN Prediction Score | 99.70% |
| Evidence Level | L2 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold (flagged internally as “Research Question”) |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data was not provided in the structured intake (flagged as a data gap). However, the literature evidence collected alongside this prediction consistently describes ofatumumab as a fully human IgG1κ monoclonal antibody that binds a distinct, membrane-proximal small-loop epitope on CD20 — different from the epitope bound by rituximab — and kills CD20⁺ B lymphocytes primarily through complement-dependent cytotoxicity (CDC), with additional antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis activity.
CLL/SLL and follicular lymphoma are both CD20⁺ indolent B-cell lymphoproliferative malignancies that sit on the same disease spectrum, differing mainly in predominant tissue distribution (blood/marrow for CLL vs. lymph node follicles for FL) rather than in the target antigen biology that ofatumumab exploits. Other anti-CD20 antibodies in the same class (rituximab, obinutuzumab) are already approved across both CLL/SLL and FL, which supports the mechanistic plausibility of the TxGNN prediction.
That said, mechanistic plausibility has not translated into regulatory approval for ofatumumab in FL despite substantial investigation. Fifteen registered trials — including three sizeable Phase 2/3 studies (n=110–346) — have tested ofatumumab monotherapy and combination regimens (with bendamustine, CHOP, bortezomib) in untreated, relapsed, and rituximab-refractory FL over more than a decade, without establishing superiority over standard anti-CD20 therapy. The largest randomized Phase 3 comparison in this space was terminated early. This pattern is consistent with the “Research Question” designation rather than a stronger recommendation.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02710643 | Phase 2 | Completed | 110 | Multicenter study of local radiotherapy ± ofatumumab in Bcl-2-stratified stage I/II follicular lymphoma |
| NCT01286272 | Phase 2 | Completed | 135 | Randomized: ofatumumab+bendamustine vs. ofatumumab+bortezomib+bendamustine in untreated FL |
| NCT01077518 | Phase 3 | Terminated | 346 | Ofatumumab+bendamustine vs. bendamustine alone in rituximab-unresponsive indolent B-NHL (incl. FL); stopped early |
| NCT01294579 | Phase 2 | Completed | 49 | Ofatumumab+bendamustine with ofatumumab maintenance in indolent B-NHL relapsed after rituximab |
| NCT00742144 | Phase 1 | Completed | 6 | Japanese PK/safety study of ofatumumab monotherapy in FL/CLL |
| NCT00394836 | Phase 2 | Completed | 116 | Single-arm study of ofatumumab in rituximab-refractory FL |
| NCT01190449 | Phase 2 | Completed | 51 | Ofatumumab monotherapy in previously untreated stage II–IV FL |
| NCT00494780 | Phase 2 | Completed | 59 | Two-dose regimens of ofatumumab + CHOP in untreated FL |
| NCT01239394 | Phase 2 | Completed | 43 | Ofatumumab as initial systemic treatment for indolent B-cell lymphoma |
| NCT00823719 | Phase 2 | Completed | 61 | Ofatumumab + ICE/DHAP salvage chemotherapy pre-transplant in relapsed/refractory aggressive lymphoma |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31174236 | 2019 | RCT | Cancer | CALGB 50904: randomized comparison of ofatumumab+bendamustine vs. triple combination with bortezomib in high-risk untreated FL |
| 38937025 | 2024 | Phase 2 / Cohort | Lancet Haematology | MRD-driven radiotherapy ± anti-CD20 mAb in early-stage FL; final results of prospective multicenter trial |
| 22409295 | 2012 | Phase 2 combination | British Journal of Haematology | Ofatumumab + CHOP as frontline therapy in untreated FL |
| 30723894 | 2019 | Phase 2 single-arm | British Journal of Haematology | CALGB 50901: single-agent ofatumumab in untreated, low/intermediate-risk FL |
| 22389254 | 2012 | Cohort | Blood | Ofatumumab monotherapy in rituximab-refractory FL; multicenter study |
| 18390837 | 2008 | Phase 1/2 | Blood | First clinical use of ofatumumab in relapsed/refractory FL |
| 28983798 | 2017 | Review | Advances in Therapy | 20-year review of anti-CD20 therapy (rituximab-focused) across B-cell malignancies including FL |
| 21083037 | 2010 | Review | Expert Review of Hematology | Emerging therapeutic strategies in follicular lymphoma |
| 26043777 | 2015 | Review | Expert Opinion on Biological Therapy | Review of ofatumumab activity in CD20⁺ B-cell lymphomas including FL |
| 22830942 | 2012 | Review | Annals of the NY Academy of Sciences | Overview of ofatumumab as first human anti-CD20 mAb for B-cell hematologic malignancies |
India Market Information
Ofatumumab currently holds no marketing authorization in India (market status: Not marketed／Not Marketed; 0 registered licenses). No product name, dosage form, or approved-indication text is available for extraction.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy / Immunotherapy (anti-CD20 monoclonal antibody, same class as rituximab/obinutuzumab) — not a conventional cytotoxic chemotherapy agent |
| Myelosuppression Risk | Low to Moderate — class safety reviews in the evidence base describe a generally favorable toxicity profile, with neutropenia and infusion-related reactions reported mainly in chemo-combination regimens |
| Emetogenicity Classification | Low — consistent with monoclonal antibody infusions rather than cytotoxic chemotherapy |
| Monitoring Items | CBC with differential (neutropenia/cytopenia), infusion-reaction monitoring during and after administration, Hepatitis B status (class-wide reactivation risk for anti-CD20 agents), immunoglobulin levels |
| Handling Protection | Standard biologic infusion precautions apply; special cytotoxic-drug handling protocols (e.g., USP<800>-type controls) are not indicated as this is not a conventional cytotoxic agent |
Safety Considerations
- Drug Interactions: 80 total interactions on file. Notable Major-level interactions include: Deferiprone, Samarium (153Sm) lexidronam, Adalimumab, Baricitinib, Certolizumab pegol, Cladribine, and Clozapine — largely reflecting compounded infection/myelosuppression risk when combined with other immunosuppressants, biologics, or bone-marrow-suppressive agents. Several Moderate-level interactions also involve live vaccines (e.g., cholera, anthrax) and other biologic immunomodulators (e.g., Alemtuzumab, Anakinra, Canakinumab), consistent with an immunosuppressed-host precaution pattern.
Detailed product-label warnings and contraindications were not available in this evidence pack; please refer to the package insert for that information.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite mechanistic plausibility and a substantial trial record (15 registered studies, including three well-powered Phase 2/3 trials), no study has demonstrated ofatumumab’s superiority over standard anti-CD20 agents (rituximab/obinutuzumab) in FL, and the largest randomized Phase 3 comparison was terminated early. Combined with zero India market presence and missing core safety documentation (MOA, warnings, and contraindications are all flagged as data gaps), there is not yet sufficient basis to proceed.
To proceed, the following is needed:
- India-specific package insert data (warnings/contraindications) — currently a Blocking data gap (DG001)
- Confirmed mechanism-of-action documentation from DrugBank or equivalent source (DG002)
- A head-to-head or meta-analytic comparison of ofatumumab vs. obinutuzumab/rituximab specifically in FL populations
- A market-entry assessment given the drug’s current absence from the India market
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.